Vaccines and Immunomodulatory Therapies for Food Allergy
- 226 Downloads
The apparent increase in food allergy prevalence has led to a surge in the amount of clinical and basic science research dedicated to the field. At the current time, allergen avoidance remains the cornerstone of treatment; however, recent clinical trials investigating various forms of immunotherapy have opened doors to the possible future application of an active treatment strategy in everyday practice. In addition, improvements in molecular biology have allowed researchers to purify, clone, and modify allergens, thus laying the groundwork for research on vaccines using modified proteins of decreased allergenicity. Finally, various allergen-nonspecific immunomodulatory therapies are also being investigated as a means to alter the immune response to food allergens. With these emerging therapeutic strategies, it is hoped that practitioners will have options in caring for their food-allergic patients in the near future.
KeywordsFood allergy Immunotherapy Immunomodulatory Treatment Therapy Vaccine Peptide Epitope Chinese herbal therapy Omalizumab Sublingual Peanut
No potential conflicts of interest relevant to this article were reported.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 19.Vickery BP, Pons L, Kulis M, et al. Individualized IgE-based dosing of egg oral immunotherapy and the development of tolerance. Ann Allergy Asthma Immunol. 2010;1005:44–450.Google Scholar
- 20.•• Varshney P, Jones SM, Scurlock AM, et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol. 2011;127:654–60. This double-blind, placebo-controlled trial built on the established data from the open-label trials. PubMedCrossRefGoogle Scholar
- 26.Enrique E, Pineda F, Malek T, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with standardized hazelnut extract. J Allergy Clin Immunol. 2005;100:283–4.Google Scholar
- 29.•• Kim Eh, Bird JA, Kulis M, et al. Sublingual immunotherapy for peanut allergy: clinical and immunological evidence of desensitization. J Allergy Clin Immunol. 2011;127:640–6. This was the initial double-blind, placebo-controlled SLIT trial for peanut allergy. There will be further data available from larger ongoing trials. PubMedCrossRefGoogle Scholar
- 38.Li S, Li XM, Burks AW, Sampson HA. Modulation of peanut allergy by peptide-based immunotherapy. J Allergy Clin Immunol. 2001;107(suppl):S233.Google Scholar
- 44.Toda M, Reese G, Gadermaier G, et al. Protein unfolding strongly modulates the allergenicity and immunogenicity of Pru p 3, the major peach allergen. J Allergy Clin Immunol. 2011, In press.Google Scholar
- 56.• Sampson HA, Leung DY, Burks AW, et al. A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol. 2011;127:1309–40. This was a collaborative study that showed a small effect of omalizumab alone for peanut allergy; it was halted due to reactions during entry oral food challenge. PubMedCrossRefGoogle Scholar
- 61.• Wang J, Patil SP, Yang N, et al. Safety, tolerability, and immunologic effects of a food allergy herbal formula in food allergic individuals: a randomized, double-blind, placebo-controlled, dose escalation, phase 1 study. Ann Allergy Asthma Immunol. 2010;105:75–84. This was the initial safety study in humans for a Chinese herbal supplement preparation that may be a realistic treatment option for food allergy in the future. PubMedCrossRefGoogle Scholar